Source - RNS
RNS Number : 8242J
Motif Bio PLC
14 September 2016

Motif Bio plc

("Motif Bio" or the "Company")


Issue of Equity


Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces that it has issued, in aggregate, 409,000 new ordinary shares in the Company ("Ordinary Shares") as part of the terms of the renegotiated Convertible Promissory Notes with Amphion Innovations plc and Amphion Innovations US Inc., as previously announced on 8 September 2016.


Application has been made for the 409,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 15 September 2016. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital will consist of 109,010,496 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.





For further information please contact:


Motif Bio plc

[email protected]

Graham Lumsden (Chief Executive Officer)




Zeus Capital Limited (NOMAD & BROKER)

+44 (0)20 3829 5000

Phil Walker/Giles Balleny


Dominic Wilson




Northland Capital Partners Limited (BROKER)

+44 (0)203 861 6625

Patrick Claridge/ David Hignell


John Howes/ Rob Rees (Broking)




Walbrook PR Ltd. (FINANCIAL PR & IR)

+44 (0) 20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893

Mike Wort

Mob: +44 (0)7900 608 002




+49 (0)89 210 2280

Raimund Gabriel



This information is provided by RNS
The company news service from the London Stock Exchange